Mark Malamood, MD, Director of Benign Esophagology in the Temple Esophageal Disease Program, provided commentary to MedPageToday regarding new research presented at Digestive Disease Week 2026. The study found that the monoclonal antibody dupilumab (Dupixent) led to significant improvements in esophageal distensibility among patients with eosinophilic esophagitis.
The topic is important as eosinophilic esophagitis is a chronic immune system disease that can cause difficulty swallowing and impact quality of life for affected individuals. New treatments that improve symptoms and underlying function are closely watched by both clinicians and patients.
Malamood’s comments were shared following the presentation of these findings, highlighting potential changes in clinical management for those living with this condition. The use of dupilumab could represent a step forward in therapy options for patients who do not respond well to existing treatments.
Digestive Disease Week is an annual event where researchers present new data on gastrointestinal diseases and therapies. Commentary from specialists like Malamood helps contextualize emerging evidence for the broader medical community.
As more data become available on dupilumab’s effects in eosinophilic esophagitis, observers will be watching for further developments and possible updates to treatment guidelines.
